Vaccination of Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype
Status:
Completed
Trial end date:
2010-11-02
Target enrollment:
Participant gender:
Summary
Patients undergo chemotherapy until remission is obtained, or disease has been stable for two
cycles of chemotherapy, or progressive disease develops.
Three to six months after completion of chemotherapy, patients who have achieved complete
clinical remission or minimal disease status receive a series of 5 injections (given 1-2
months apart) of a vaccine consisting of 0.5 mg autologous tumor-derived immunoglobulin (Id)
conjugated to KLH. The vaccine is administered with subcutaneous QS-21 as an immunological
adjuvant....